Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Double Act: How a Single Molecule Can Attract and Repel Growing Brain Connections

Published: Saturday, August 09, 2014
Last Updated: Saturday, August 09, 2014
Bookmark and Share
The 3D structure of Netrin-1 bound to DCC shows Netrin-1 binds to two DCC molecules in different ways.

How can you find the same thing both attractive and repulsive? For growing neurons, the answer is in how they engage with it. The findings, published online in Neuron, stem from the 3D structure of Netrin-1 bound to one of the sensor molecules - receptors - the cell uses to detect it.

The work, by scientists at the European Molecular Biology Laboratory (EMBL) in Hamburg, Germany, the Dana-Farber Cancer Institute affiliated to Harvard Medical School in Boston, the USA, and Peking University in Beijing, China, could also have implications for cancer treatment.

“Although this is a challenging area for drug design, we found a mode of interaction that could be exploited to make cells respond to Netrin in a specific way, for instance to control proliferation or trigger programmed cell death,” says Rob Meijers, who led the work at EMBL.

Our brain’s ‘wiring’ is a set of protrusions that run from one neuron to another, like stretched-out arms. As connections between neurons are established - in the developing brain and throughout life - each of these wires, or axons, grows out from a neuron and extends through the brain until it reaches its destination: the neuron it is connecting to. To choose its path, a growing axon senses and reacts to different molecules it encounters along the way. One of these molecules, Netrin-1, posed an interesting puzzle: an axon can be both attracted to and repelled from this cue. The axon’s behaviour is determined by two types of receptor on its tip: DCC drives attraction, while UNC5 in combination with DCC drives repulsion.

When the scientists determined the 3D structure of Netrin-1 bound to DCC, they found the answer to this conundrum. The structure showed that Netrin-1 binds not to one, but to two DCC molecules. But most surprisingly, it binds those two molecules in different ways.

“Normally a receptor and a signal are like lock-and-key, they have evolved to bind each other and are highly specific – and that’s what we see in one Netrin site,” says Meijers. “But the second is a very unusual binding site, which is not specific for DCC.”

Most of the second binding site does not connect directly to a receptor. Instead, it requires small molecules that act as middle-men. These intermediary molecules seem to have a preference for UNC5, so if the axon has both UNC5 and DCC receptors, Netrin-1 will bind to one copy of UNC5 via those molecules and one copy of DCC at the DCC-specific site. This triggers a cascade of events inside the cell that ultimately drives the axon away from the source of Netrin-1, Yan Zhang’s lab at Peking University found. The researchers surmise that, if an axon has only DCC receptors, each Netrin-1 molecule binds two DCC molecules, which results in the axon being attracted to Netrin-1.

“So by controlling whether or not UNC5 is present on its tip, an axon can switch from moving towards Netrin to moving away from it, weaving through the brain to establish the right connection,” says Jia-Huai Wang, who heads labs at Dana-Farber Cancer Institute and Peking University, and co-initiated the research.

Knowing how neurons switch from being attracted to Netrin to being repelled opens the door to devise ways of activating that switch in other cells that respond to Netrin cues, too. For instance, many cancer cells produce Netrin to attract growing blood vessels that bring them nourishment and allow the tumour to grow, so switching off that attraction could starve the tumour, or at least prevent it from growing. On the other hand, when cancers metastasize they often stop being responsive to Netrin. In fact, the DCC receptor was first identified as a marker for an aggressive form of colon cancer, and DCC stands for ‘deleted in colorectal cancer’. Since colorectal cancer cells have no DCC, they are ‘immune’ to the programmed cell death that would normally follow once they move away from the lining of the gut and no longer have access to Netrin. As a result, these tumour cells continue to move into the bloodstream, and metastasize to other tissues.

Meijers and colleagues are now investigating how other receptors bind to Netrin-1, and exactly how the intermediary molecules ‘choose’ their preferred receptor. The answers could one day enable researchers to steer a cell’s response to Netrin, ultimately changing its fate.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

It Runs in the Family
Distantly related viruses share a common machinery for replication.
Saturday, May 23, 2015
Cancer by Remote-Control
Overlooked DNA shuffling drives deadly paediatric brain tumour.
Tuesday, June 24, 2014
Rigged to Explode?
Inherited mutation links exploding chromosomes to cancer.
Wednesday, April 11, 2012
Making Enough Red Blood Cells
EMBL scientists identify molecules that ensure red blood cell production.
Monday, June 14, 2010
First-ever Blueprint of a Minimal Cell is More Complex than Expected
EMBL and CRG scientists reveal what a self-sufficient cell can’t do without.
Monday, November 30, 2009
Researchers Identify Protein Recycling Mechanism That Helps Protect From Genetic Disorders
EMBL study sheds new light on a proof-reading process that helps protecting humans from genetic diseases.
Monday, May 04, 2009
Genome Wide Study of Transcription in Yeast Redefines the Concept of Promoters
The EMBL study contradicts the established notion that promoters support transcription in one direction only.
Thursday, January 29, 2009
Digital Zebrafish Embryo Provides the First Complete Developmental Blueprint of a Vertebrate
Researchers at the European Molecular Biology Laboratory (EMBL) have generated a digital zebrafish embryo - the first complete developmental blueprint of a vertebrate.
Tuesday, October 14, 2008
Scientific News
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!